German and Swedish Cancer Researchers Join Forces
Erlangen/Stockholm - The German biotech company responsif GmbH and scientists from the prestigious Karolinska Institute in Stockholm, Sweden, have recently signed a cooperation agreement, which will bring a promising new treatment for cancer one step closer to clinical trials. The Swedish cancer researchers working in the Department of Oncology & Pathology in the Section for Experimental Oncology are now using an “anchoring” technique developed by responsif to pack tumour antigens into virus capsoids. The aim is to create an anti-tumour vaccine, which will mobilise the body's own immune defences against cancer cells.
As part of the cooperation agreement, the Swedish scientists have obtained a license option for the specific use of the anchor technology. The agreement also gives them the option of acquiring industrial partners within the next two years to assist them in developing this technology up to market maturity.
“Our consistent patent strategy has proved to be the right one”, commented Dr. Christian Reiser, Managing Director of responsif, recently at the BioTechnica in Hannover, Germany. “We are very pleased that these clinicians plan to deploy the anchor technology developed by responsif in the battle against cancer.”
With the licensing agreement, the two partners have also entered into a scientific collaboration aimed at advancing the preclinical investigation of an anti-tumour vaccine based on the viral capsoid technology developed by the biotechnologists in Erlangen. The capsoid technology evolved from the idea of using Polyoma virus-like particles (VLPs) as delivery systems for tumour antigens. Since these particles do not contain any viral genetic information, moreover, they are not infectious.
In addition to the anchor technology, responsif GmbH is working on another immunotherapeutic approach using autologous cancer cells from patients with advanced stage cancer. The company is a spin-off of the former Division of Molecular Therapy at november AG, a biotech company traded in the Prime Standard segment of the German Stock Exchange.